Skip to content
Baltimore News Journal – Lifestyle
Author:
Tris Pharma, Inc.
Tris Pharma Named a BioSpace 2027 Best Places to Work Winner
November 16, 2026
Tris Pharma Earns 2026 Great Place To Work Certification™
October 14, 2026
Tris Pharma Introduces New 30-Count Bottle Size for QuilliChew ER® (methylphenidate HCl) Extended-Release Chewable Tablets for Attention Deficit Hyperactivity Disorder (ADHD)
September 14, 2026
Tris Pharma to Showcase ADHD Leadership and Commitment to Individualized Care at Fall 2026 Medical Conferences
September 1, 2026
Tris Pharma Expands Support for People Living with ADHD Through New Partnerships with Calm Health and ADHD Central
August 12, 2026
Tris Pharma to Present on Dual NOP/MOP Receptor Agonist in Pain Management and Substance Use Disorder at the College on Problems of Drug Dependence (CPDD) 88th Annual Scientific Meeting, 2026
June 11, 2026
Tris Pharma Announces FDA Grant of Orphan Drug Designation for TRN-257 (Oxybate for Extended-Release Oral Suspension) a Once-Nightly, Low-Sodium Oxybate Product for Idiopathic Hypersomnia
June 10, 2026
Tris Pharma Introduces a New 60 mL Bottle Size for DYANAVEL® XR (amphetamine) Extended-Release Oral Suspension CII
June 8, 2026
Tris Pharma Announces Presentation on The Complexity and Management of ADHD at Psych Congress Elevate 2026
June 2, 2026